PeptidePrices is an independent research-peptide price comparison and vendor-evidence site, founded in April 2026. We publish original market data, a daily price index and a public library of certificates of analysis. Journalists, podcasters and researchers are welcome to cite and quote it.
Each study is dated, published with its methodology and released under CC BY 4.0, so it can be checked and reused with attribution.
Census · September 19, 2026
Growth-hormone peptide storefront census
12 growth-hormone-axis compounds checked across a frozen panel of 995 research-peptide storefront domains: 11,940 domain-by-compound checks, with availability and price distributions for each compound. Forbes cited it on September 25, 2026.
A traffic-calibrated model of 995 research-use-only peptide storefront domains, based on 47.75 million estimated visits from May to July 2026. Its headline figure, about $4.31 billion in annualized gross sales, is a modeled estimate, not reported revenue.
13 publicly posted FDA warning letters sent to research-peptide storefronts. When checked on August 23, 2026, 10 of the warned businesses still exposed peptide sales through public or account-gated catalogs.
We announced the Peptide Market Intelligence Index 2026 in a paid press release distributed via PR Newswire. Yahoo Finance and Morningstar carried the release. These are syndicated copies of our own announcement, not independent editorial coverage.
10,000+ in-stock listings across 101 compounds, compared by the whole-package price needed to reach the comparison amount. Each listing shows its own check date; the current index is checked through November 6, 2026.
Hand-written reviews of 47 independent testing laboratories that issue peptide certificates of analysis, written to help researchers corroborate a vendor's reports.
714 of 995 research-peptide storefronts in our panel listed tesamorelin (71.8%), the most widely sold of the 12 growth-hormone-axis compounds we checked.
10 of 13 research-peptide businesses that received a publicly posted FDA warning letter were still exposing peptide sales when we checked on August 23, 2026.
A certificate of analysis is attached to a PeptidePrices listing only when it matches the exact vendor, compound, strength and unit. With no exact match, the listing shows no certificate.
Only a certificate the issuing laboratory confirms in its own records earns our COA verified badge. Reports from laboratories with no public record stay visible, explicitly marked as not verified.
Affiliate status has zero weight in a PeptidePrices evidence score. Comparison tables order listings by price.
Please attribute to PeptidePrices and link the page the figure came from. Live figures change; quote the date shown on that page.
Story angles we can comment on
Verifying a certificate of analysis
Why a COA is only as good as the laboratory record behind it, how cropped or recycled reports slip through, and what an exact vendor, compound and strength match looks like in practice.
Enforcement and what stays online
What our FDA warning-letter census shows about storefronts that keep selling after a warning letter.
The size and shape of the research-peptide market
How many storefronts exist, which compounds they carry, and how our storefront census and market model were built, including their limits.
Prices, testing and research-use-only compliance
How prices compare across vendors, which tests buyers should look for beyond purity, and how we score vendors on a published methodology with affiliate status given zero weight.
About the team
PeptidePrices was founded in April 2026 by two co-founders and is operated by PeptidePrices LLC as an independent project. It is not owned by, or operated in partnership with, any peptide vendor.
PeptidePrices vendor reviews, vendor comparisons and blog posts carry his byline. He co-maintains the published evidence rubric and is the press contact for interviews and data requests.